Please use this identifier to cite or link to this item:
Title: Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique
Authors: Tinto, Halidou
Sevene, Esperança
Dellicour, Stephanie
Calip, Gregory S.
Alessandro, Umberto D’
Macete, Eusébio
Nakanabo-Diallo, Seydou
Kazienga, Adama
Valea, Innocent
Sorgho, Hermann
Valá, Anifa
Augusto, Orvalho
Rupérez, María
Menendez, Clara
Ouma, Peter
Desai, Meghna
Kuile, Feiko Ter
Stergachis, Andy
Keywords: Pregnancy
Issue Date: 2015
Publisher: BioMed Central
Citation: Tinto, H., Sevene, E., Dellicour, S., Calip, G. S., d'Alessandro, U., Macete, E., Nakanabo-Diallo, S., Kazienga, A., Valea, I., Sorgho, H., Valá, A., Augusto, O., Ruperez, M., Menendez, C., Ouma, P., Desai, M., Ter Kuile, F., & Stergachis, A. (2015). Assessment of the safety of antimalarial drug use during early pregnancy (ASAP): protocol for a multicenter prospective cohort study in Burkina Faso, Kenya and Mozambique. Reproductive health, 12, 112.
Abstract: A major unresolved safety concern for malaria case management is the use of artemisinin combination therapies (ACTs) in the first trimester of pregnancy. There is a need for human data to inform policy makers and treatment guidelines on the safety of artemisinin combination therapies (ACT) when used during early pregnancy. Methods The overall goal of this paper is to describe the methods and implementation of a study aimed at developing surveillance systems for identifying exposures to antimalarials during early pregnancy and for monitoring pregnancy outcomes using health and demographic surveillance platforms. This was a multi-center prospective observational cohort study involving women at health and demographic surveillance sites in three countries in Africa: Burkina Faso, Kenya and Mozambique [( Identifier: NCT01232530)]. The study was designed to identify pregnant women with artemisinin exposure in the first trimester and compare them to: 1) pregnant women without malaria, 2) pregnant women treated for malaria, but exposed to other antimalarials, and 3) pregnant women with malaria and treated with artemisinins in the 2nd or 3rd trimesters from the same settings. Pregnant women were recruited through community-based surveys and attendance at health facilities, including antenatal care clinics and followed until delivery. Data from the three sites will be pooled for analysis at the end of the study. Results are forthcoming. Discussion Despite few limitations, the methods described here are relevant to the development of sustainable pharmacovigilance systems for drugs used by pregnant women in the tropics using health and demographic surveillance sites to prospectively ascertain drug safety in early pregnancy.
Appears in Collections:Artigos Publicados em Revistas Cientificas - FAMED

Files in This Item:
File Description SizeFormat 
2015 - Sevene, Esperança1 .pdf475.38 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.